We evaluated GH, IGF-1 and IGFBP-3 concentrations in ten acromegalic patients before and after treatment with subcutaneous octreotide (OCT-sc) and long-acting octreotide (OCT-LAR). We also evaluated the acute and short-period treatment (post 21 days) with octreotide as an index to test tolerance and responsiveness to both formulations. Patients were also evaluated after 6 months of treatment with each drug. Pre-treatment fasting GH (µg/l; IFMA), GH nadir during oGTT and IGF-1 (µg/l; IRMA) levels were 13.9±6.3; 11.4±6.3; 717±107, respectively. Fasting GH […]